The plasma leptin/adiponectin ratio predicts first cardiovascular event in men
Kappelle, Paul J.W.H.; Dullaart, Robin P. F.; van Beek, Andre P.; Hillege, Hans L.; Wolffentutel, Bruce H. R.
Published in:
European Journal of Internal Medicine

DOI:
10.1016/j.ejim.2012.06.013

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2012

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 01-03-2019
The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: 
A prospective nested case–control study

Paul J.W.H. Kappelle a,1, Robin P.F. Dullaart a,⁎,1 André P. van Beek a,1, 
Hans L. Hillegé b,1, Bruce H.R. Wolfenbuttel a,1

a Department of Endocrinology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands 
b Department of Cardiology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands

A R T I C L E   I N F O

Article history:
Received 12 March 2012
Received in revised form 11 June 2012
Accepted 13 June 2012
Available online 20 July 2012

Keywords:
Adiponectin 
Cardiovascular disease
Leptin
Leptin/adiponectin ratio
Total cholesterol/HDL cholesterol ratio

A B S T R A C T

Objective: The plasma leptin/adiponectin (L/A) ratio has been proposed as a preferential marker of atherosclerosis susceptibility compared to leptin and adiponectin alone. We determined the extent to which the L/A ratio predicts incident cardiovascular disease (CVD) taking account of clinical risk factors, microalbuminuria, the total cholesterol/HDL cholesterol (TC/HDL-C ratio), triglycerides, high sensitive C-reactive protein (hs-CRP) and insulin sensitivity (homeostasis model assessment (HOMAβ)).

Methods: A community-based prospective nested case–control study was carried out in 103 non-diabetic men who developed a first cardiovascular event (cases) and 106 male control subjects (no clinically manifest CVD and no lipid lowering drug use at baseline; median follow-up of 3.0 and 10.5 years, respectively). Plasma leptin, adiponectin, the leptin/adiponectin (L/A) ratio, as well as hs-CRP, HOMAβ and the TC/HDL-C ratio were determined at baseline.

Results: Plasma leptin levels and the L/A ratio were higher in cases vs. controls (p=0.002 for both), but the difference in adiponectin was not significant (p=0.10). Age-adjusted incident CVD was associated with plasma leptin, adiponectin and the L/A ratio (p=0.045 to p=0.001). The relationships of incident CVD with plasma leptin (p=0.19) and adiponectin (p=0.073) lost statistical significance after additional adjustment for smoking, waist circumference, hypertension, microalbuminuria, the TC/HDL-C ratio, hs-CRP and HOMAβ. In this fully adjusted analysis, the L/A ratio remained predictive of incident CVD (hazard ratio: 1.40 (95% CI 1.05–1.87), p=0.024).

Conclusion: This study suggests that the L/A ratio may be a preferential marker of a first cardiovascular event in men compared to plasma leptin and adiponectin levels alone.
© 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

1. Introduction

Leptin and adiponectin are secreted by adipose tissue, and represent the most abundant adipokines in human plasma [1–5]. Despite intensive study, the relevance of leptin and adiponectin in cardiovascular disease (CVD) prediction is still unsettled. Although high plasma leptin levels predict incident CVD, this relationship is to a considerable extent attenuated by obesity [6]. A meta-analysis revealed that higher plasma adiponectin levels confer only a modest cardioprotective effect [7]. Intriguingly, pro-atherogenic effects of leptin and anti-atherogenic effects of adiponectin could paradoxically disappear in people who are already suffering from advanced atherosclerosis [8,9].

Based on intima–media thickness and other surrogate outcome measures it has been proposed that the L/A ratio may be preferable over separate leptin and adiponectin measurements in CVD risk assessment [10–13], but the advantage of the L/A ratio in predicting subclinical atherosclerosis is uncertain [14,15]. Information concerning the relevance of the L/A ratio in clinical cardiovascular outcome prediction is limited. In the Monica/KORA Augsburg studies, incident CVD was related to plasma levels of leptin, adiponectin, as well as to the L/A ratio in age-, sex- and survey-adjusted analyses [16]. Of note, none of these adipokine measures predicted incident CVD after additional controlling for clinical and non-clinical risk factors [16]. It is well appreciated that plasma levels of high-sensitive C-reactive protein (hs-CRP), as a marker of chronic subclinical inflammation, are correlated positively to plasma leptin and inversely to adiponectin [17–19]. Of further importance, various measures of insulin sensitivity are strongly dependent on the L/A ratio, emphasizing the role of adipocyte dysfunction in the pathogenesis of insulin resistance [20]. It is, therefore, relevant to take account of chronic subclinical inflammation...
and insulin sensitivity when evaluating the relationship of cardiovascular outcome with the L/A ratio.

In the present study, we determined the extent to which incident CVD is associated with the L/A ratio. To this end a prospective nested case–control study was carried out among participants of the community-based Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort. The setup of this study enabled us to take account of conventional clinical and non-clinical risk factors, microalbuminuria, hs-CRP and insulin sensitivity.

2. Subjects and methods

2.1. Study population and design

The local medical ethics committee approved the study, and all participants gave written informed consent. The present prospective nested case–control study was carried out among participants of the PREVEND cohort. Details of the PREVEND study have been published elsewhere (www.PREVEND.org,[21]). The PREVEND study comprises a prospective study in a predominantly Caucasian population that was started in 1997. To this end all inhabitants of the city of Groningen, the Netherlands, aged 28 to 75 years were sent a questionnaire and a vial to collect a first-morning-void urine sample (prescreening). Of these subjects, 40,856 responded (47.8%) and returned a vial to a central laboratory for urinary albumin and creatinine assessment. After exclusion of patients with insulin-treated diabetes mellitus and pregnant women, all subjects with a urinary albumin concentration of ≥10 mg/L (n=7768) were invited of which 6000 participated. Furthermore, 3394 randomly selected subjects with a urinary albumin concentration of <10 mg/L were invited of which 2592 participated. These 8592 subjects participated in the baseline screening and constitute the actual PREVEND cohort.

Men without a history of myocardial infarction, major ischemia, percutaneous transluminal coronary angioplasty or coronary artery bypass graft at baseline were eligible for the present nested case–control study, as described [21]. Diabetes mellitus, use of lipid lowering drugs and urinary albumin excretion >300 mg/24 h at baseline were additional exclusion criteria. Initial selection of cases was men who experienced an event during follow-up as defined below. The original time frame of observation included the period from enrolment (1997) until 31 December 2003 or 31 December 2002 until which date information regarding specific causes of death follow up information was available [23]. For the present study an extended follow-up, censored at 31 December 2008 was used. Control subjects were randomly selected from the baseline sample applying similar exclusion criteria as for the cases [21]. The current report includes 103 cases and 106 controls in whom in addition to serum lipids, apolipoprotein B and apoA-I were determined by nephelometry using commercially available reagents [23]. Plasma leptin was analyzed using LumineX xMAP technology (Lincor Research Inc. St. Charles, MO, USA). Lincoplex panel B (HADK-2-61K-B). Validation experiments have shown that leptin levels measured with this technology are strongly correlated with assay results obtained by enzyme-linked immunosorbent assay (ELISA) obtained from Linco Inc. ([24]; data provided by the manufacturer). Total adiponectin was measured by enzyme-linked immunosorbent assay (Linco Research Inc., St. Charles, MO, USA, cat no E2HADP-61K). The within-assay coefficients of variation for leptin and adiponectin were 8.9% and 6.4%, respectively. Insulin was measured by microparticle enzyme immunoassay (AxSYM Insulin assay; Abbott Laboratories, Abbott Park II, USA), hs-CRP was measured by nephelometry with a threshold of 0.18 mg/L.[23].

2.3. Statistical analyses

SPSS 18 was used for data analysis. Two-sided p-values≤0.05 were considered significant.

Data are expressed as mean±SD or in median (interquartile range). Differences in variables between cases and controls were compared with unpaired Student’s t-tests. Between group differences in dichotomous variables were compared by χ2-analysis. Because of skewed distribution, logarithmically transformed values of leptin, adiponectin, the L/A ratio, triglycerides, hs-CRP, insulin and HOMA2 were used in the analysis. Between group differences in leptin, adiponectin and the L/A ratio were also determined after controlling for age. Univariate relationships were assessed by Pearson’s correlation coefficients.

Associations between incident CVD and plasma levels of leptin, adiponectin and the L/A ratio were determined using age-adjusted Cox proportional hazards analyses. The date of a first event was used to calculate duration of follow-up. The proportional hazards assumption was not violated in any of the models. Hazard ratios (HRs) are reported per SD change with 95% confidence interval (95% CI). HRs of adipokines and the L/A ratio were also determined after further adjustment for clinical variables, the TC/HDL-C ratio, triglycerides and microalbuminuria, as well as after additional adjustment for HOMA2 and hs-CRP. We used Cox proportional hazard analyses, because some controls were lost to follow-up before census date.

The whole PREVEND cohort consists of a random sample of subjects with urinary albumin concentration <10 mg/L and all subjects with urinary albumin concentration ≥10 mg/L. [25]. Since enrichment for subjects with higher degrees of albuminuria could induce bias due to oversampling of subjects with urinary albumin concentration ≥10 mg/L, we also estimated risk in a sensitivity analysis. This sensitivity analysis was done among those subjects included in the present nested case–control study who made part of the so-called “random sample” of the PREVEND cohort, i.e. all subjects with urinary albumin concentration <10 mg/L and a subset of subjects with urinary albumin concentration ≥10 mg/L, exactly as described previously [25].
3. Results

Median follow-up was 3.0 (10th to 90th percentile, 0.9–5.8) years in cases and 10.5 (10th to 90th percentile, 9.1–11.1) years in control subjects. Cases were older, more obese, smoked more frequently, had a higher prevalence of hypertension and microalbuminuria, had higher hs-CRP levels and were more insulin resistant compared to control subjects (Table 1). Plasma TC, non-HDL-C, the TC/HDL-C ratio and triglycerides were higher, whereas HDL-C was lower in cases. Likewise, apoB and the apoB/apoA-I ratio was increased, whereas apoA-I was decreased in cases. Plasma leptin levels and the L/A ratio were elevated in cases, although the difference in adiponectin was not significant (Table 1). In age-adjusted analyses, plasma adiponectin (p = 0.013) and the L/A ratio (p = 0.006) were different in cases compared to controls, but the difference in plasma leptin did not reach significance (p = 0.065).

In all subjects combined, leptin and the L/A ratio were correlated positively with waist, HOMA_β, hs-CRP, albuminuria, the TC/HDL-C ratio, the apoB/apoA-I ratio and triglycerides (Table 2). Adiponectin was correlated inversely with waist, HOMA_β, the TC/HDL-C ratio, the apoB/apoA-I ratio and triglycerides. Comparable relationships of the leptin, adiponectin and the L/A ratio with these variables were observed in cases and control subjects separately (Table 2). The L/A ratio was neither significantly correlated with age in all subjects combined (r = 0.108, p = 0.121), nor in cases (r = −0.082, p = 0.423) and in control subjects (r = 0.092, p = 0.346) separately.

As shown in Table 2 (models 1), age-adjusted incident CVD was associated positively with leptin and inversely with adiponectin. Incident CVD was also positively predicted by the L/A ratio with the point estimates of the hazard ratio for CVD being slightly higher than that of plasma leptin alone. After additional adjustment for smoking, waist circumference, hypertension, microalbuminuria, the total cholesterol/HDL cholesterol ratio and triglycerides (models 2), the relationships of incident CVD with leptin, adiponectin and the L/A ratio remained significant (models 2). The relationships of incident CVD with leptin and adiponectin were, however, no longer statistically significant after further controlling for hs-CRP and HOMA_β (models 3). Of note, the L/A ratio remained predictive of incident CVD in this fully adjusted model. Alternatively, in fully adjusted analyses with the apoB/apoA-I ratio instead of the TC/HDL-C ratio (cf. models 3) the relationships of incident CVD with plasma leptin (HR 1.21 (95% CI, 0.91–1.61), p = 0.19) and adiponectin (HR 0.82 (95% CI, 0.60–1.02), p = 0.073) were again not significant, whereas the L/A ratio still predicted CVD (HR 1.38 (95% CI, 1.03–1.85), p = 0.03) (Table 3).

A sensitivity analysis was carried out among subjects making part of the so-called random sample of the PREVEND cohort. This analysis again revealed that CVD risk was associated with the L/A ratio (model 1: HR 1.35 (95% CI 1.08–1.70), p = 0.009; model 2: HR 1.49 (95% CI 1.11–2.01), p = 0.009; model 3: HR 1.37 (95% CI 1.08–1.90), p = 0.062).

4. Discussion

This prospective nested case–control study demonstrates that in age-adjusted analyses incident CVD is positively related to plasma leptin and the L/A ratio, and inversely to plasma adiponectin. Thus, in this study among men without clinically manifest atherosclerosis at baseline there was no evidence for a putative reverse epidemiology phenomenon, which has been implicated in paradoxically opposite relationships of these adipokines with CVD in elderly people and in subjects with advanced manifestations of atherosclerotic disease [8,9,26]. Moreover, after additional adjustment for clinical risk factors, as well as for plasma lipids and microalbuminuria, the association of incident CVD with all these adipokine measures remained statistically significant. Of note, in fully adjusted models in which we also accounted for chronic subclinical inflammation and insulin sensitivity, only the relationship of incident CVD with the L/A ratio remained statistically significant. The current study, therefore, suggests that the L/A ratio may be a preferential marker of adipokine-associated first cardiovascular events in predominantly middle-aged men compared to plasma leptin and adiponectin levels alone.

It is likely that leptin and adiponectin contribute to the pathogenesis of (obesity-related) atherosclerosis via several interrelated metabolic pathways, including effects on inflammatory processes and modulation of insulin sensitivity [1–5]. In addition, adiponectin may directly affect the synthesis of apoA-I, the major HDL apolipoprotein, as well as the metabolism of triglyceride-rich lipoproteins [27,28]. As expected, the L/A ratio was strongly correlated with the waist circumference, hs-CRP, HOMA_β, the TC/HDL-C ratio and triglycerides [17–20]. We also observed a correlation with higher urinary albumin excretion, which is considered a cardiovascular risk marker as well [29,30]. These robust relationships underscore the necessity to take account of all these factors when evaluating the extent to which leptin, adiponectin and the L/A ratio may predict incident CVD. Indeed, we found no statistically independent effects of plasma leptin and adiponectin levels alone on incident CVD in fully adjusted analyses.

The currently documented independent contribution of the L/A ratio to first cardiovascular events even in fully adjusted analysis needs to be compared with the results of the prospective Monica/KORA Augsburg studies that comprised middle aged men and women who were initially free of clinically manifest coronary heart disease. In that report, no independent effect of the L/A ratio on incident CHD could be demonstrated [16]. Although the precise reasons for the apparent discrepancy remain to be clarified, there are several methodological differences. The Monica/KORA Augsburg report had a case–cohort design and included higher numbers of men and women, whereas recruitment of subjects was carried out at multiple surveys. In the PREVEND project, in contrast, subject recruitment was carried out within a limited time frame. Furthermore, the current study had a nested case–control design, making that the number of participants in our study was smaller. In addition, we adjusted for hypertension and the presence of microalbuminuria. The Monica/KORA Augsburg report took account of physical activity and alcohol consumption. On the other hand, both studies used essentially similar clinical cardiovascular end-points, and accounted for lipoprotein-related risk primarily by using the TC/HDL-C ratio, which has emerged as a

### Table 1
Clinical characteristics, microalbuminuria, plasma glucose, high sensitive C-reactive protein (hs-CRP), insulin sensitivity (homeostasis model assessment (HOMA_β)), lipids and apolipoproteins (apo), leptin, adiponectin and the leptin/adiponectin (L/A) ratio in cases and controls subjects.

<table>
<thead>
<tr>
<th></th>
<th>Cases (n = 103)</th>
<th>Control subjects (n = 106)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>58 ± 10.3</td>
<td>47 ± 12</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMU (kg/m²)</td>
<td>27.0 ± 3.5</td>
<td>25.8 ± 3.2</td>
<td>0.005</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>97 ± 10.2</td>
<td>92 ± 9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension (n, %)</td>
<td>58 (56%)</td>
<td>31 (29%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking (n, %)</td>
<td>57 (55%)</td>
<td>38 (36%)</td>
<td>0.005</td>
</tr>
<tr>
<td>Microalbuminuria (n, %)</td>
<td>31 (30%)</td>
<td>14 (13%)</td>
<td>0.007</td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>2.09 (1.10–3.54)</td>
<td>0.97 (0.46–2.71)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>4.3 ± 0.7</td>
<td>4.8 ± 0.6</td>
<td>0.29</td>
</tr>
<tr>
<td>Insulin (mU/L)</td>
<td>9.7 ± 6.13</td>
<td>7.3 ± 5.10</td>
<td>0.028</td>
</tr>
<tr>
<td>HOMA_β (mU × mmol/L)</td>
<td>2.0 ± 1.25</td>
<td>1.6 ± 1.23</td>
<td>0.002</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>6.18 ± 1.16</td>
<td>5.58 ± 1.03</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.06 ± 0.23</td>
<td>1.21 ± 0.32</td>
<td>0.002</td>
</tr>
<tr>
<td>TC/HDL-C ratio</td>
<td>6.41 ± 2.22</td>
<td>4.96 ± 1.60</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>1.60 (1.07–2.38)</td>
<td>1.17 (0.84–1.55)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Apo B (g/L)</td>
<td>1.23 ± 0.38</td>
<td>1.06 ± 0.25</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Apo A-I (g/L)</td>
<td>1.24 ± 0.27</td>
<td>1.33 ± 0.22</td>
<td>0.005</td>
</tr>
<tr>
<td>ApoB/ApoA-I ratio</td>
<td>1.04 ± 0.36</td>
<td>0.82 ± 0.23</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Leptin (μg/L)</td>
<td>3.92 (2.34–7.54)</td>
<td>2.89 (2.01–5.00)</td>
<td>0.002</td>
</tr>
<tr>
<td>Adiponectin (mg/L)</td>
<td>15.56 (9.52–30.09)</td>
<td>19.97 (11.54–30.51)</td>
<td>0.10</td>
</tr>
<tr>
<td>L/A ratio (μg/mg)</td>
<td>0.26 (0.12–0.56)</td>
<td>0.16 (0.08–0.32)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Data in mean ± SD or in median (interquartile range). BMI, body mass index; HDL, high density lipoproteins; and TC/HDL-C ratio, total cholesterol/HDL cholesterol ratio.
sensitive C-reactive protein (hs-CRP), urinary albumin excretion (UAE), the total cholesterol/HDL cholesterol (TC/HDL-C) ratio and triglycerides in cases and control subjects.

Hazard ratios (HRs with 95% confidence intervals) of leptin, adiponectin and the leptin/adiponectin (L/A) ratio for incident cardiovascular disease by Cox proportional hazard analysis. HRs are given per 1 SD increase.

<table>
<thead>
<tr>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leptin HR (95% CI)</td>
<td>1.25 (1.01–1.55)</td>
<td>1.32 (1.02–1.71)</td>
</tr>
<tr>
<td>p-value</td>
<td>0.045</td>
<td>0.037</td>
</tr>
<tr>
<td>Adiponectin</td>
<td>0.74 (0.62–0.89)</td>
<td>0.88 (0.65–1.00)</td>
</tr>
<tr>
<td>p-value</td>
<td>0.001</td>
<td>0.047</td>
</tr>
<tr>
<td>L/A ratio</td>
<td>1.40 (1.14–1.71)</td>
<td>1.50 (1.15–1.97)</td>
</tr>
<tr>
<td>p-value</td>
<td>0.001</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Leptin, adiponectin and the L/A ratio values are logarithmically transformed.

Models 1: adjusted for age.
Models 2: adjusted for age, smoking, waist circumference, hypertension, microalbuminuria, the total cholesterol/HDL cholesterol ratio and triglycerides.
Models 3: adjusted for age, smoking, waist circumference, hypertension, microalbuminuria, the total cholesterol/HDL cholesterol ratio, triglycerides, high sensitive C-reactive protein and insulin sensitivity (homeostasis model assessment).
References


